SecBot SecBot
8-K ·Filed Aug 10, 2026

REPL

Replimune Group, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001104659-26-093042
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The ~13% pricing discount signals urgency, likely tied to cash runway for phase 3 IGNYTE-3 confirmatory trial and TUDRIQEV launch costs. Monitor for insider lock-up expiry; 45-day period starts after Aug 10 prospectus supplement, first potential unlocking ~Sep 24. If stock trades above $12.06 after close, some hedge unwinding may create volatility.

DirectionBearish
Confidencehigh
Horizonimmediate

TUDRIQEV

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved and commercially available in the U.S. since October 2026.
Next catalyst
None dated

What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.67
T+0 close · Aug 10, 2026 · via day close
Latest settled
+51.06%
T+60 · $20.65
Vs SPY
+53.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $13.67entry
  2. T+1 · 3mo ago −0.15%α +0.17% · $13.65
  3. T+5 · 3mo ago +7.02%α +7.07% · $14.63
  4. T+20 · 2mo ago +8.05%α +8.96% · $14.77
  5. T+60 · 14d ago +51.06%α +53.48% · $20.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune Group priced a $150M underwritten offering of 9.7M common shares at $12.06/share and 2.7M pre-funded warrants at $12.0599/warrant. Estimated net proceeds are approximately $140.5M. The dilutive offering more than doubles the company's cash balance but adds ~18% share overhang, typical for a commercial-stage biotech funding pipeline and commercialization.

Key Facts

  • Offering of 9,701,490 common shares + 2,736,340 pre-funded warrants (exercise price $0.0001)
  • Aggregate gross proceeds of approximately $150M; estimated net proceeds ~$140.5M
  • Offering priced at $12.06 per share, a ~13% discount to the $12.40 opening on Aug 7 pre-filing
  • Underwriters: Leerink Partners, J.P. Morgan, Cantor Fitzgerald
  • Closing expected August 11, 2026 with customary conditions
  • 45-day lock-up on insiders from date of final prospectus supplement

Financial Impact

~$140.5M net proceeds added to cash; 9.7M new shares + 2.7M pre-funded warrant shares = 12.4M total new common-equivalent shares, ~18% dilution on ~69M est. pre-offer shares (assuming ~70M pre-offer)

dilutioncashshareCount

Risk Factors

  • 18% dilution pressures near-term EPS; no revenue data in filing to offset
  • No stated use of proceeds detail, investors face uncertainty on cash burn rate allocation
  • Pre-funded warrants allow immediate secondary selling at any time (ex $0.0001 exercise), adding overhang
  • Biotech sector risk: confirmatory phase 3 data (IGNYTE-3) still pending; offering may signal need for more capital before readout

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-093042
Document: tm2622673d1_ex4-1.htm0001104659-26-093042
Document: tm2622673d1_8k.htm0001104659-26-093042
Document: tm2622673d1_ex99-1.htm0001104659-26-093042
Document: tm2622673d1_ex5-1.htm0001104659-26-093042
Document: 0001104659-26-093042-index-headers.html0001104659-26-093042
Document: 0001104659-26-093042-index.html0001104659-26-093042
Document: 0001104659-26-093042.txt0001104659-26-093042

Track record

32 reports on REPL

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026